文献速递细菌感染、耐药与抗菌药物医院感染防控

实体器官移植受者革兰阴性菌血症的口服抗生素治疗:倾向评分加权回顾性观察研究

Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该回顾性观察研究纳入2016至2021年麻省总医院与布莱根妇女医院系统中实体器官移植受者的非复杂性革兰阴性菌血症事件,采用倾向评分逆概率治疗加权模型比较口服抗生素降阶梯治疗与持续静脉治疗。结果显示两组死亡率、菌血症复发及重新启用静脉抗生素无显著差异,口服组平均住院时间缩短1.97天,静脉组艰难梭菌感染和其他治疗相关并发症的 odds 分别高8.4倍和6.4倍。

要点

  • 口服降阶梯治疗与持续静脉治疗在死亡率、菌血症复发和重新启用静脉抗生素方面无显著差异。
  • 口服组平均住院时间较静脉组缩短1.97天(95%CI -0.39至3.56天;P=0.005)。
  • 静脉组发生艰难梭菌感染的 odds 为口服组8.4倍(95%CI 1.5-46.6;P=0.015)。

核心结论

  • 口服降阶梯治疗有效,且与较少的治疗相关不良事件相关。

研究设计与样本

  • 倾向评分加权回顾性观察研究,纳入2016至2021年麻省总医院与布莱根妇女医院系统中实体器官移植受者的非复杂性革兰阴性菌血症事件。
  • 口服组120例菌血症事件(来自107例患者),静脉组42例事件(来自40例患者)。
  • 采用基于倾向评分的逆概率治疗加权模型比较口服降阶梯与持续静脉治疗。

主要发现

  • 两组死亡率、菌血症复发及重新启用静脉抗生素无显著差异。
  • 口服组平均住院时间较静脉组缩短1.97天(95%CI -0.39至3.56天;P=0.005)。
  • 静脉组发生艰难梭菌感染的 odds 为口服组8.4倍(95%CI 1.5-46.6;P=0.015)。
  • 静脉组发生其他治疗相关并发症的 odds 为口服组6.4倍(95%CI 1.9-20.9;P=0.002)。
  • 静脉组55%的患者需要置入隧道式中心静脉导管;两组治疗时长无差异。

关键数值与推荐

  • 纳入标准为非复杂性革兰阴性菌血症,且病原体对具有可接受生物利用度的口服抗生素敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed the safety and efficacy of oral antibiotic step-down therapy for uncomplicated gram-negative blood stream infections in solid-organ transplant recipients. METHODS: We identified all solid-organ transplant recipients within the Massachusetts General and Brigham and Women's Hospital systems from 2016 to 2021 with uncomplicated gram-negative bacteremia involving an organism susceptible to an acceptably bioavailable oral antibiotic agent. Using inverse probability of treatment-weighted models based on propensity scores adjusting for potential clinical confounders, we compared outcomes of those transitioned to oral antibiotics with those who continued intravenous (IV) therapy for the duration of treatment. Primary endpoints were mortality, bacteremia recurrence, and reinitiation of IV antibiotics. Secondary endpoints included length of stay, Clostridioides difficile infection, treatment-associated complications, and tunneled central venous catheter placement. RESULTS: A total of 120 bacteremia events from 107 patients met inclusion criteria in the oral group and 42 events from 40 patients in the IV group. There were no significant differences in mortality, bacteremia recurrence, or reinitiation of IV antibiotics between groups. Patients transitioned to oral antibiotics had an average length of stay that was 1.97 days shorter (95% confidence interval [CI], -.39 to 3.56 days; P = .005). Odds of developing C. difficile and other treatment-associated complications were 8.4 times higher (95% CI, 1.5-46.6; P = .015) and 6.4 times higher (95% CI, 1.9-20.9; P = .002), respectively, in the IV group. Fifty-five percent of patients in the IV group required tunneled catheter placement. There was no difference in treatment duration between groups. CONCLUSIONS: Oral step-down therapy was effective and associated with fewer treatment-related adverse events.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nussbaum EZ, Koo S, Kotton CN, et al. Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study. Clin Infect Dis. 2024. PMID: 38195100. doi:10.1093/cid/ciae007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。